NCCN and ASCO guidelines support the use of ZOMETA^® in patients like Marta

National Comprehensive Cancer Network (NCCN) guidelines¹⁶

• ZOMETA or pamidronate should be given (with calcium and vitamin D) to patients with bone metastases with expected survival >3 months and creatinine <3.0 mg/dL

American Society of Clinical Oncology (ASCO) guidelines¹⁷

• Initiation of therapy
  • — In patients with evidence of bone destruction, IV ZOMETA 4 mg or
    pamidronate 90 mg is recommended
  • — Starting bisphosphonates in women without evidence of bone destruction is
    not recommended
  • — Bone pain should not be a factor

• Duration of therapy
  • — The optimal duration of treatment is not known
  • — “...once initiated, intravenous bisphosphonates [should] be continued until evidence of substantial decline in a patient’s general performance status”

ZOMETA is proven in clinical trials to delay and reduce SREs in breast cancer through 25 months⁷

Achieve maximum efficacy—dose with ZOMETA 4 mg every 3 to 4 weeks